This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mHealth and uHealth, is properly cited. The complete bibliographic information, a link to the original publication on https://mhealth.jmir.org/, as well as this copyright and license information must be included.
https://mhealth.jmir.org/2024/1/e56475/https://mhealth.jmir.org/2025/1/e70895/WeChatnutrition managementovarian cancerchemotherapymobile health
We agreed with the authors of the letter to the editor [1] that Figure 7 simply describes “the changes in blood cells.” Our study [2] only focused on the effect of nutritional status on the inflammatory response of the patients but neglected an important point: the changes in blood cells such as “leukocytes, lymphocytes, neutrophils, and platelets” were also closely related to the occurrence of bone marrow suppression (BMS) in the patients [3]. Figure 7 illustrates that the nutritional intervention program in this study can reduce the occurrence of BMS in patients to a certain extent.
We couldn’t agree more with the letter’s suggestion. We would like to include the benefits of improved BMS in the Discussion section of our study, which would primarily include the following:
Improvement in BMS can contribute to the patient’s quality of life during chemotherapy [4].
Reversal of the hematocrit condition corresponds to a reduction in the number or degree of the patient’s chemotherapy symptoms: elevated neutrophils lead to lower levels of fatigue, fewer persistent or chronic infections, and less nausea/vomiting [5].
An increase in hemoglobin improved the patient’s appetite and reduced vertigo [6].
An increase in the number of platelets reduced the incidence of hemorrhage [7].
None declared.
AbbreviationsBMS
bone marrow suppression
ReferencesLianCFanYLiJClarifying blood indices in patients with ovarian cancerJMIR Mhealth Uhealth202513e7089510.2196/70895TianXLiuYZhangJEfficacy of a WeChat-Based, multidisciplinary, full-course nutritional management program on the nutritional status of patients with ovarian cancer undergoing chemotherapy: randomized controlled trialJMIR Mhealth Uhealth202411412e5647510.2196/5647539496160Ten BergMJvan den BemtPMLAShantakumarSThrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort studyDrug Saf201112134121151116010.2165/11594310-000000000-0000022077503CrawfordJHerndonDGmitterKWeissJThe impact of myelosuppression on quality of life of patients treated with chemotherapyFuture Oncol202420211515153010.2217/fon-2023-051338587388CrawfordJMooreDCMorrisonVADaleDUse of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: a review of adherence to present guidelines for usageCancer Treat Res Commun20212910046610.1016/j.ctarc.2021.10046634655862BryerEHenryDChemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practiceInt J Clin Transfus201810236213110.2147/IJCTM.S187569Thrombocytopenia (low platelet count)American Cancer Society2025-08-06https://www.cancer.org/cancer/managing-cancer/side-effects/low-blood-counts/bleeding.html